Rubius Therapeutics
620 Memorial Drive
Suite 100W
Cambridge
Massachusetts
02139
United States
Website: http://www.rubiustx.com/
126 articles with Rubius Therapeutics
-
Flagship Pioneering has partnered with Novo Nordisk to build a portfolio of potential treatments for cardiometabolic and rare diseases.
-
Rubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
5/10/2022
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today reported first quarter 2022 financial results and provided a business update.
-
Rubius Therapeutics to Announce First Quarter 2022 Financial Results
4/26/2022
Rubius Therapeutics, Inc. (Nasdaq: RUBY), today announced plans to report first quarter financial results on Tuesday, May 10, 2022, before market open.
-
Noubar Afeyan, founder of Flagship Pioneering and Moderna, spoke at an event hosted by the Institute of Global Health Innovation.
-
Shares fell in several life sciences companies at the close of the market Friday on apparently lackluster early data from their respective research projects. We look into each one below:
-
Rubius Therapeutics to Host Investor Webcast to Discuss Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Patients with Advanced Solid Tumors on April 8, 2022, at 1:15 PM ET
4/7/2022
Rubius Therapeutics, Inc. announced the details of its webcast to discuss updated clinical data from the ongoing monotherapy Phase 1 arm of the Phase 1/2 clinical trial of RTX-240 in patients with advanced solid tumors and relapsed/refractory acute myeloid leukemia on April 8, 2022, at 1:15 p.m. ET.
-
Rubius Therapeutics to Present Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 at the American Association of Cancer Research Annual Meeting
3/8/2022
Rubius Therapeutics, Inc. (Nasdaq: RUBY), today announced that the Company will present updated results from its single-agent Phase 1 clinical trial of RTX-240 in advanced solid tumors in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting.
-
Rubius Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
2/25/2022
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today reported fourth quarter and full year 2021 financial results.
-
Rubius Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results
2/14/2022
Rubius Therapeutics, Inc. (Nasdaq: RUBY), today announced plans to report fourth quarter and full year 2021 financial results on Friday, February 25, 2022, before market open.
-
Rubius Therapeutics to Present at the Virtual Guggenheim Healthcare Talks and SVB Leerink Global Healthcare Conference in February 2022
2/1/2022
Rubius Therapeutics, Inc. announced that the executive management team will present and host meetings with investors at the virtual Guggenheim Healthcare Talks and SVB Leerink Global Healthcare Conference in February.
-
Today, Noubar Afeyan, founder of Flagship Pioneering, published the platform development company’s 2022 Annual Letter, and in it, outlined what he sees as the four top forces shaping the future of biotech.
-
Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors
1/13/2022
Rubius Therapeutics, Inc. today announced that the first patient has been dosed in its Phase 1/2 clinical trial of RTX-224 for the treatment of patients with certain relapsed/refractory or locally advanced solid tumors.
-
Rubius Therapeutics Recaps 2021 Achievements and Outlines 2022 Objectives Across the RED PLATFORM at the 40th Annual J.P. Morgan Healthcare Conference
1/10/2022
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, provided an overview of the Company’s achievements in 2021 and outlined its objectives for 2022.
-
Rubius Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced Pablo J. Cagnoni, M.D., president and chief executive officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference.
-
Rubius Therapeutics to Highlight the Power of its RED PLATFORM®, Significant Advances Across Red Cell Therapeutic Oncology Pipeline and New Type 1 Diabetes Program at Platform and Pipeline Day
12/16/2021
Rubius Therapeutics, Inc. (Nasdaq: RUBY), today announced significant advances from its RED PLATFORM and across its pipeline of Red Cell Therapeutics (RCTs) at the Company’s first Pipeline and Platform Day.
-
Rubius Therapeutics Named to the List of Top Places to Work in Massachusetts by the Boston Globe
12/2/2021
Rubius Therapeutics, Inc. today announced that for the second year in a row the Boston Globe has named the Company among its annual Top Places to Work in Massachusetts.
-
Rubius Therapeutics to Host Virtual Preclinical Pipeline and Platform Technology Day on December 16, 2021
12/1/2021
Rubius Therapeutics, Inc. announced that it will host a virtual investor and analyst event focused on the company’s RED PLATFORM® and preclinical pipeline in oncology and autoimmunity, in particular type 1 diabetes.
-
Rubius Therapeutics to Participate in Evercore ISI 4th Annual HealthCONx Conference
11/23/2021
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that Pablo J. Cagnoni, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference.
-
Rubius Therapeutics Presents Preclinical Data for RTX-224, a Broad Immune Costimulatory Agonist, at the Society for Immunotherapy of Cancer’s Annual MeetingU.S. FDA Recently Cleared Investigational New Drug Application for RTX-224
11/12/2021
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced the poster presentation of preclinical data for RTX-224.
-
Cell therapy veteran Christina Coughlin is taking over the reins of the privately-held company developing natural killer immune cells to battle cancer.